{"id":"acthar-high-dose-80-u","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes / irritability"},{"rate":null,"effect":"Increased infection risk"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Fluid retention / edema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acthar binds to melanocortin-2 receptors on adrenocortical cells, triggering the release of endogenous glucocorticoids and mineralocorticoids. This endogenous steroid production provides anti-inflammatory and immunosuppressive effects. The high-dose formulation (80 U) is used for acute exacerbations of conditions requiring rapid corticosteroid elevation.","oneSentence":"Acthar is a synthetic adrenocorticotropic hormone (ACTH) that stimulates the adrenal cortex to produce and release cortisol and other corticosteroids.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:08.852Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infantile spasms (West syndrome)"},{"name":"Acute exacerbations of multiple sclerosis"},{"name":"Rheumatoid arthritis"},{"name":"Systemic lupus erythematosus"},{"name":"Polymyositis and dermatomyositis"}]},"trialDetails":[{"nctId":"NCT02779153","phase":"PHASE4","title":"Acthar SLE (Systemic Lupus Erythematosus)","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2016-10","conditions":"Systemic Lupus Erythematosus (SLE), Repository Corticotropin Injection","enrollment":""},{"nctId":"NCT02382523","phase":"PHASE4","title":"Acthar on Proteinuria in IgA Nephropathy Patients","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"IgA Nephropathy, Proteinuria","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Repository Corticotropin Injection"],"phase":"marketed","status":"active","brandName":"Acthar high dose (80 U)","genericName":"Acthar high dose (80 U)","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acthar high dose (80 U) has been studied in clinical trials for conditions such as Systemic Lupus Erythematosus (SLE), IgA Nephropathy, and Proteinuria. The exact mechanism of Acthar high dose (80 U) is not specified in the provided information, but it is known to be a Repository Corticotropin Injection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}